Yes, there is an oral GLP-1 medication. Oral semaglutide, sold under the brand name Rybelsus, is the only FDA-approved GLP-1 receptor agonist available in pill form. It was first approved in 2019 for blood sugar control in type 2 diabetes, and it has since gained approval for reducing cardiovascular risk in people with type 2 diabetes. A higher-dose version is also being studied for weight loss specifically.
How an Oral GLP-1 Pill Works
GLP-1 is a hormone your body naturally releases after eating. It signals your pancreas to produce insulin, slows digestion, and reduces appetite. Injectable GLP-1 medications like Ozempic and Wegovy deliver semaglutide directly into the bloodstream through a subcutaneous shot, bypassing the digestive system entirely.
Getting a protein-based drug to survive the stomach is the core challenge with a pill. Your stomach acid and digestive enzymes would normally break semaglutide apart before it could be absorbed. Rybelsus solves this by pairing semaglutide with a compound called SNAC (salcaprozate sodium). When the tablet dissolves, SNAC raises the local pH in the stomach, which limits the activation of digestive enzymes that would destroy the drug. It also temporarily changes the lining of stomach cells, making them more permeable so semaglutide can pass through into the bloodstream. This effect is short-lived and fully reversible.
How Effective It Is Compared to Injections
Oral semaglutide works, but at currently approved doses it’s somewhat less potent than the injectable version. In clinical trials, the average blood sugar (A1c) reduction compared to placebo was 1.1% for oral semaglutide versus 1.56% for injectable semaglutide. Weight loss followed a similar pattern: oral semaglutide produced about 2.3 kg of weight loss beyond placebo, while injectable semaglutide achieved roughly 4.5 kg.
That said, when researchers directly compared the two formulations in a real-world study over 26 weeks, the gap narrowed. The oral group lost 3.74% of their body weight from baseline, while the injectable group lost 4.02%. The difference in blood sugar reduction actually favored the oral form slightly, though neither difference was statistically significant.
A Higher Dose for Weight Loss
The currently approved doses of Rybelsus (up to 14 mg) were designed for diabetes management, not weight loss. But a 50 mg oral semaglutide tablet has been tested in a phase 3 trial called OASIS 1, and the results were striking. Over 68 weeks, people with overweight or obesity who took the 50 mg dose lost an average of 15.1% of their body weight, compared to 2.4% with placebo. More than half the participants lost at least 15% of their body weight, and about one-third lost 20% or more. Those numbers put it in the same territory as injectable Wegovy. This higher dose is not yet FDA-approved for weight management but is under review.
How to Take It
Oral semaglutide has specific dosing instructions that matter for how well it works. You take it first thing in the morning on a completely empty stomach, with no more than 4 ounces (about 120 mL) of plain water. Then you wait at least 30 minutes before eating, drinking anything else, or taking other medications. Taking it with food dramatically reduces how much of the drug gets absorbed, because food dilutes the SNAC compound that protects and transports semaglutide through the stomach lining. Waiting longer than 30 minutes can actually increase absorption slightly.
The dose is gradually increased over the first two months to reduce the chance of nausea and other GI side effects. With the original formulation, you start at 3 mg daily for the first 30 days (a dose too low to affect blood sugar, purely for adjustment), then move to 7 mg, and potentially up to 14 mg if more blood sugar control is needed. A newer formulation (called R2) follows the same timeline but uses different strengths: 1.5 mg, then 4 mg, then up to 9 mg.
Side Effects
The side effect profile of oral semaglutide is similar to injectable GLP-1 medications. Gastrointestinal symptoms are the most common issue. In the OASIS 1 trial testing the 50 mg weight loss dose, 80% of participants reported some GI side effect, compared to 46% on placebo. Most of these were mild to moderate, primarily nausea, and they tend to be worst during the dose escalation period before settling down.
The gradual dose titration schedule exists specifically to ease you through this adjustment period. Some people still find the nausea difficult enough to stop treatment. In the orforglipron trials (a next-generation oral GLP-1, discussed below), between 5% and 10% of participants discontinued due to side effects.
Who Should Not Take It
Oral semaglutide is not appropriate for everyone. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or a condition called multiple endocrine neoplasia syndrome type 2. Anyone who has had a severe allergic reaction to semaglutide should also avoid it. The strict fasting requirement can also be a practical barrier for people who struggle with morning routines or take other time-sensitive medications first thing in the morning.
Next-Generation Oral GLP-1 Pills in Development
Rybelsus requires a special absorption-enhancing compound because semaglutide is a large peptide molecule. A new class of oral GLP-1 drugs takes a fundamentally different approach: small-molecule compounds that can be absorbed more like a conventional pill.
Orforglipron, developed by Eli Lilly, is the furthest along. In a phase 3 trial published in the New England Journal of Medicine, over 3,100 adults with obesity took orforglipron or placebo for 72 weeks. The highest dose (36 mg) produced an average weight loss of 11.2%, compared to 2.1% with placebo. More than half the people on that dose lost at least 10% of their body weight, and about 18% lost 20% or more. Orforglipron does not require the strict fasting protocol that Rybelsus does, which could make it significantly easier to use day to day.
Pfizer was developing a competing small-molecule called danuglipron, which showed weight loss of up to 12.9% beyond placebo in a phase 2b study. However, Pfizer discontinued development after a potential case of drug-induced liver injury was identified in a subsequent trial, combined with regulatory feedback. So orforglipron is currently the leading next-generation candidate, though it has not yet received FDA approval.